• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

UK Tops Europe for Regulatory Affairs Vacancies


May 17, 2016.

The UK tops Europe for regulatory affairs vacancies, according to new research from Vacancysoft.

The company looked at 1,711 vacancies in regulatory affairs across the European Economic Area and Switzerland between April 2014 and March 2016 and found that 70 per cent originated from just five key markets, the largest being the UK with 30 per cent. Germany followed with a 16 per cent, following a year-on-year increase of 119 per cent. Switzerland 12 per cent, France 6 per cent and Belgium 6 per cent. Vacancies in the traditional pharmaceutical sector make up the vast majority of the total, 84 per cent. Almost all of the remaining vacancies were found to be with CROs (15 per cent of the total).

In terms of growth, Germany’s 119 per cent was highest year-on-year gain to March 2016, followed by the UK with 84 per cent. Switzerland, France and Belgium all more or less tracked the European average with 66 per cent, 68 per cent and 62 per cent, respectively. In the broader European market, only two major markets saw a drop: the Netherlands, with 5 per cent market share, and Sweden, with 3 per cent. Conversely, Italy showed a 162 per cent increase driven by a strong surge in activity by the CRO PPD.

At the city level, Basel had the highest number of vacancies, with half of all Swiss openings, representing 6 per cent of the total market. Just behind are Cambridge, UK (5 per cent), London (4 per cent), Harlow, UK (3 per cent) and Holzkirchen in Germany (3 per cent). Holzkirchen saw the biggest year-on-year growth, with a 288 per cent increase, and Macclesfield, UK, with a 200 per cent rise, driven by high vacancy numbers at Hexel and AstraZeneca, respectively. 

To see the Vacancysoft report, visit http://files.vacancysoft.com/reports/Vacancysoft_ClinicalProfessionals_Pharmaceuticals_Report_Spring2016.pdf

Related Videos